KROS

Keros Therapeutics, Inc. Common Stock

9.33

USD

+0.16

+1.74%

Nov 10, 15:59 UTC -5

Closed

After-Market

9.32

-0.01

-0.05%

Keros Therapeutics, Inc. Common Stock (KROS) Earnings

KROS Earnings Reports

Positive Surprise Ratio

KROS beat 15 of 27 last estimates.

56%

Next Report

Date of Next Report

Mar 02, 2027

Estimate for Q4 26 (Revenue/ EPS)

$437.14K

-$1.82

Implied change from Q3 26 (Revenue/ EPS)

-98.91%

-360.00%

Implied change from Q4 25 (Revenue/ EPS)

+13.54%

+111.63%

Keros Therapeutics, Inc. Common Stock earnings per share and revenue

On Nov 05, 2026, KROS reported earnings of 0.70 USD per share (EPS) for Q3 26, beating the estimate of -0.95 USD, resulting in a 173.01% surprise. Revenue reached 40.01 million, compared to an expected 15.06 million, with a 165.67% difference. The market reacted with a -0.95% price change (close before vs. close after earnings).

Looking ahead to Q4 26, -- analysts forecast an EPS of -1.82 USD, with revenue projected to reach 437.14 thousand USD, implying an decrease of -360.00% EPS, and decrease of -98.91% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Kura Oncology, Inc.

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.83

Actual

-$0.78

Surprise

+7.00%

Olema Pharmaceuticals, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.63

Actual

-$0.73

Surprise

-14.53%

Autolus Therapeutics plc - ADR

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.21

Surprise

-27.20%

Protalix BioTherapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.03

Actual

$0.05

Surprise

+265.02%

PepGen Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.27

Actual

-$0.28

Surprise

-1.19%

Humacyte, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.09

Actual

-$0.07

Surprise

+22.91%

Seer, Inc. Class A Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.25

Actual

-$0.25

Surprise

+1.96%

Scholar Rock Holding Corporation Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.86

Actual

-$0.81

Surprise

+6.18%

TELA Bio, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.13

Surprise

+20.54%

Atossa Therapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.90

Actual

-$0.56

Surprise

+38.31%

FAQ

What were Keros Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?

For Q3 2026, Keros Therapeutics, Inc. Common Stock reported EPS of $0.70, beating estimates by 173.01%, and revenue of $40.01M, 165.67% above expectations.

How did the market react to Keros Therapeutics, Inc. Common Stock's Q3 2026 earnings?

The stock price moved down -0.95%, changed from $9.45 before the earnings release to $9.36 the day after.

When is Keros Therapeutics, Inc. Common Stock expected to report next?

The next earning report is scheduled for Mar 02, 2027.

What are the forecasts for Keros Therapeutics, Inc. Common Stock's next earnings report?

Based on -- analysts, Keros Therapeutics, Inc. Common Stock is expected to report EPS of -$1.82 and revenue of $437.14K for Q4 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.